PLXDC1 and neoplasm: Additionally, we conducted a PDAC cohort of 8 patients with immune‐checkpoint blockade (ICB) treatment (camrelizumab, a PD‐1 inhibitor) or combined treatment (abraxane plus gemcitabine chemotherapy along with ICB) and performed scRNA‐seq on the pre‐treatment tumor biopsies to explore the association between PLXDC1+ TPSCs and ICB effectiveness.